Abstract 100: Real-world clinical outcomes associated with first line treatments in patients with advanced non-small cell lung cancer without EGFR mutation or ALK rearrangement based on AACR GENIE
Hemanth Kanakamedala(Johnson & Johnson (United States)), Ariadna Holynskyj(Novartis (United States)), Sara Bruce Wirta(Novartis (Switzerland)), Nydia Caro(Novartis (United States)), Wen-Hsing Wu, Rohit Borker(Novartis (United States)), Beilei Cai(Novartis (United States))
Cited by 0
Related Papers
Real-World Treatment Patterns of Sacubitril/Valsartan: A Longitudinal Cohort Study in Germany
|European Journal of Heart Failure|2019|66
Burden of heart failure on caregivers in China: results from a cross-sectional survey
|Drug Design Development and Therapy|2018|48
<p>Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden</p>
|Clinical Epidemiology|2019|45
Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries
|Diabetes Therapy|2014|41
Burden of heart failure on patients from China: results from a cross-sectional survey
|Drug Design Development and Therapy|2018|31